We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Omburtamab

News List

First Drug Coming Soon as Pharmaceutical Companies Take Moves in the B7-H3 Immune Target Products Layout PharmaSources.com/Yi
May 23, 2022
Based on public information, TAA06 is an independently developed B7-H3-targeted CAR-T therapy of PersonGen. The drug was granted the Orphan Drug Designation (ODD) for treating neuroblastoma by the FDA (Food and Drug Administration) in March of this year.
Y-mAbs announces FDA clearance of IND for its Lutetium-177 labelled omburtamab antibody pharmaceutical-business-review
October 21, 2020
Y-mAbs Therapeutics announced that the U.S. Food and Drug Administration has cleared the Company’s Investigational New Drug application for 177Lu-omburtamab-DTPA for the treatment of medulloblastoma, which is the most common type of primary brain cancer..